EyePoint Pharmaceuticals Files Definitive Proxy Statement

TL;DR

<b>EyePoint Pharmaceuticals filed its Definitive Proxy Statement, outlining its strategic shift and pipeline advancements.</b>

AI Summary

EyePoint Pharmaceuticals, Inc. (EYPT) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. EyePoint Pharmaceuticals filed a Definitive Proxy Statement (DEF 14A) on April 26, 2024. The filing concerns the company's annual meeting and related matters. EyePoint completed its transformation into a clinical-stage biopharmaceutical company with the out-license of the YUTIQ franchise. The company is focused on advancing its pipeline of sustained-delivery treatments, including EYP-1901 (DURAVYU™). EYP-1901 is an investigational sustained release product for wet age-related macular degeneration (wAMD) and non-proliferative diabetic retinopathy.

Why It Matters

For investors and stakeholders tracking EyePoint Pharmaceuticals, Inc., this filing contains several important signals. The filing details the company's transition to a clinical-stage biopharmaceutical entity, signaling a focus on R&D and pipeline development. Key pipeline programs like EYP-1901 are highlighted, indicating future growth potential and strategic direction.

Risk Assessment

Risk Level: low — EyePoint Pharmaceuticals, Inc. shows low risk based on this filing. The filing is a routine DEF 14A proxy statement, which typically contains information about corporate governance and shareholder proposals, not material financial or operational changes.

Analyst Insight

Review the proxy statement for details on upcoming shareholder votes, executive compensation, and any new governance proposals.

Key Numbers

• 2024-04-26 — Filing Date (Date the DEF 14A was filed)
• 2024-06-20 — Period of Report (Conformed period of report for the filing)
• 0000950170-24-049067 — Accession Number (Unique identifier for the filing)
• 000-51122 — SEC File Number (SEC file number for EyePoint Pharmaceuticals)

Key Players & Entities

• EyePoint Pharmaceuticals, Inc. (company) — Registrant
• pSivida Corp. (company) — Former company name
• pSivida LTD (company) — Former company name
• YUTIQ (product) — Franchise out-licensed by EyePoint
• EYP-1901 (product) — Lead pipeline program
• DURAVYU™ (product) — Formulation of EYP-1901
• vorolanib (drug) — Component of EYP-1901
• Durasert E™ (technology) — Drug delivery technology

FAQ

Industry Context

EyePoint Pharmaceuticals operates in the biopharmaceutical industry, focusing on developing sustained-delivery treatments for serious retinal diseases.

Regulatory Implications

The filing is a standard DEF 14A proxy statement, subject to SEC regulations governing shareholder communications and corporate disclosures.

What Investors Should Do

1. Review the full DEF 14A filing for details on shareholder meeting agenda items.
2. Examine executive compensation disclosures within the proxy statement.
3. Note any proposed changes to the company's board of directors or governance structure.

Year-Over-Year Comparison

This is a DEF 14A filing, which is a routine annual disclosure. No specific comparison to a prior filing's content is available from the provided text.

Key Financial Figures

• $82.5 million — h the May 2023 out-license of YUTIQ for $82.5 million plus future royalties and the December
• $230 million — ecember 2023 completion of a successful $230 million follow-on equity financing. We ended th
• $331 million — apitalized with cash and investments of $331 million with no debt. When it comes to matter
• $850,000 — compensation limit contained therein to $850,000 for ongoing directors in any calendar y
• $1,100,000 — oing directors in any calendar year and $1,100,000 for new directors in any calendar year.

Filing Documents

• eypt_def_14a_04-26-2024.htm (DEF 14A) — 1629KB
• img83600834_0.jpg (GRAPHIC) — 31KB
• img83600834_1.jpg (GRAPHIC) — 6KB
• img83600834_2.jpg (GRAPHIC) — 4KB
• img83600834_3.jpg (GRAPHIC) — 31KB
• img83600834_4.jpg (GRAPHIC) — 17KB
• img83600834_5.jpg (GRAPHIC) — 31KB
• img83600834_6.jpg (GRAPHIC) — 229KB
• img83600834_7.jpg (GRAPHIC) — 237KB
• img83600834_8.jpg (GRAPHIC) — 175KB
• img83600834_9.jpg (GRAPHIC) — 137KB
• 0000950170-24-049067.txt (&nbsp;) — 2865KB

From the Filing

DEF 14A 1 eypt_def_14a_04-26-2024.htm DEF 14A DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to 240.14a-12 EyePoint Pharmaceuticals, Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required Fee paid previously with preliminary materials Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 480 Pleasant Street, Suite C400 Watertown, MA 02472 United States April 26, 2024 To Our Stockholders, 2023 was an exceptional year for EyePoint as we executed on our mission to bring innovative, life-changing therapeutics to patients living with serious retinal diseases. We completed our transformation into a clinical-stage biopharmaceutical company with the out-license of the YUTIQ franchise, and now we are focused on advancing and expanding our pipeline of innovative sustained-delivery treatments to provide a brighter future for those at risk of losing their sight. We are focused on advancing and expanding our pipeline of innovative sustained-delivery treatments to provide a brighter future for those at risk of losing their sight. EyePoint&#x2019;s bioerodible Durasert E drug delivery technology provides a best-in-class sustained release intravitreal insert for treating serious retinal diseases. This technology enables a constant, sustained drug release known as zero order kinetics. We have built a potential multi-billion-dollar pipeline around this innovative drug delivery technology. In 2023, we made great progress with our lead pipeline program, EYP-1901 (DURAVYU), an investigational sustained release product that consists of vorolanib, a selective and patent-protected tyrosine kinase inhibitor, formulated in Durasert E. During the year, we continued our record of strong execution and completed enrollment in two Phase 2 clinical trials in wet age-related macular degeneration (wAMD) and non-proliferative diabetic retinopathy (NPDR). In December 2023, we reported positive topline efficacy and safety data from our Phase 2 DAVIO 2 clinical trial in wAMD, achieving all primary and secondary endpoints We believe these strong results underscore the potential of DURAVYU (vorolanib intravitreal insert) to be a paradigm-altering treatment for patients suffering from VEGF-mediated retinal diseases. Looking ahead, we expect to report topline data for the Phase 2 PAVIA clinical trial in NPDR in the second quarter of this year and to initiate the first pivotal Phase 3 wAMD trial, the LUGANO trial, in the second half of this year, with the second pivotal wAMD trial called the LUCIA trial to follow. In January 2024, we initiated our third Phase 2 clinical trial for DURAVYU, the VERONA trial for diabetic macular edema (DME), and we look forward to reporting topline results in the first quarter of 2025. DURAVYU brings a new mechanistic approach to the treatment of VEGF-mediated retinal diseases by combining zero order kinetic release and pan-VEGF receptor inhibition, inhibiting the effects of all VEGF isoforms, resulting in enhanced efficacy and extended durability. We remain highly encouraged by the growing body of positive clinical data for DURAVYU and its potential as a differentiated therapeutic option with sustained delivery over 6-9 months, and we are optimistic that DURAVYU has the potential to change the current treatment paradigm for VEGF-mediated retinal diseases. Turning to our early pipeline, in 2023 we announced a new preclinical program, EYP-2301, which delivers a promising TIE-2 agonist, razuprotafib, formulated in Durasert E. We believe that delivering EYP-2301 intravitreally has the potential to offer new sight-saving treatment for patients with severe retinal disease, either alone or in combination with anti-VEGFs. We continue to evaluate additional molecules for sustained delivery in Durasert E including complement inhibition and rare diseases and hope to update you on those programs later this year. In addition, we significantly strengthened our balance sheet with the May 2023 out-license of YUTIQ for $82.5 million plus future royalties and the December 2023 completion of a successful $230 million follow-on equity financing. We ended the year well-capitalized with cash and investments of $331 million with no debt. When it comes to matters of sight, innovation is our vision. To support our pipeline progress and meet the long-term needs

View Full Filing

View this DEF 14A filing on SEC EDGAR